Evidence map›Paper›PMID 37608014›Full record

ArticleScientific reports2023

Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy.

Kensuke Kataoka, Keishi Oda, Hajime Takizawa, Takashi Ogura, Atsushi Miyamoto, Yoshikazu Inoue, Shinobu Akagawa, Seishu Hashimoto, Tomoo Kishaba, Koji Sakamoto and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. A multidimensional index with SpORespiratory research & clinical practice · 2026
    Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kensuke KataokaDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.
Keishi OdaDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
Hajime TakizawaDepartment of Respiratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
Takashi OguraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Atsushi MiyamotoDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan.
Yoshikazu InoueClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
Shinobu AkagawaDepartment of Respiratory Medicine, National Hospital Organization Tokyo Hospital, Tokyo, Japan.
Seishu HashimotoDepartment of Respiratory Medicine, Tenri Hospital, Tenri, Nara, Japan.
Tomoo KishabaDepartment of Respiratory Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.
Koji SakamotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Naoki HamadaGraduate School of Medical Sciences, Kyushu University, Research Institute for Diseases of the Chest, Fukuoka, Japan.
Kazuyoshi KuwanoDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Masayuki NakayamaDepartment of Internal Medicine, Division of Pulmonary Medicine, Jichi Medical University, Shimono, Tochigi, Japan.
Masahito EbinaDepartment of Respiratory Medicine, Tohoku Medical and Pharmaceutical University Medical School, Sendai, Miyagi, Japan.
Noriyuki EnomotoDepartment of Internal Medicine, Second Division, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
Kenichiro AtsumiDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Shinyu IzumiDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
Yoshinori TaninoDepartment of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Hiroshi OhnishiDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Takafumi SudaDepartment of Internal Medicine, Second Division, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Yasuhiro KondohDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan. kondoh@tosei.or.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While high-level evidence is lacking, numerous retrospective studies have depicted the value of supplemental oxygen in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, and its use should be encouraged where necessary. The clinical course and survival of patients with IPF who have been introduced to oxygen therapy is still not fully understood. The objective of this study was to clarify overall survival, factors associated with prognosis, and causes of death in IPF patients after the start of oxygen therapy. This is a prospective cohort multicenter study, enrolling patients with IPF who started oxygen therapy at 19 hospitals with expertise in interstitial lung disease. Baseline clinical data at the start of oxygen therapy and 3-year follow-up data including death and cause of death were assessed. Factors associated with prognosis were analyzed using univariable and multivariable analyses. One hundred forty-seven eligible patients, of whom 86 (59%) were prescribed ambulatory oxygen therapy and 61 (41%) were prescribed long-term oxygen therapy, were recruited. Of them, 111 died (76%) during a median follow-up of 479 days. The median survival from the start of oxygen therapy was 537 ± 74 days. In the univariable analysis, low body mass index (BMI), low forced vital capacity (FVC), low diffusion capacity (D

Indexed as

AsthmaIdiopathic Pulmonary FibrosisCohort StudiesHumansOxygenPrognosisProspective StudiesPulmonary Disease, Chronic ObstructiveRetrospective StudiesOxygen

Identifiers

PMID37608014
PMCPMC10444790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.